

UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF NEW YORK

IVOCLAR VIVADENT, INC.,

Plaintiff,

v.

Civil No. _____

TALLADIUM, INC.,

Defendant.

COMPLAINT

Ivoclar Vivadent, Inc. (“Ivoclar”), for its Complaint against Talladium, Inc. (“Talladium”), alleges as follows:

The Parties

1. Ivoclar is a Delaware corporation with a principal place of business at 175 Pineview Drive, Amherst, NY 14228. It is a leading developer and supplier of dental products.

2. Talladium is a California corporation with a principal place of business at 27360 West Muirfield Lane, Valencia, CA 91355. Talladium manufactures and sells dental products for distribution throughout the United States, including New York.

Jurisdiction and Venue

3. This is a patent infringement action brought under the patent laws of the United States, 35 U.S.C. Section 101, *et seq.*, including 35 U.S.C. Section 271.

4. Ivoclar seeks damages for patent infringement and an injunction preventing Talladium from making, using, selling, or offering to sell, and from inducing others to make, use, sell, or offer to sell, Ivoclar's patented technology without Ivoclar's permission.

5. This Court has subject matter jurisdiction under 28 U.S.C. Sections 1331 and 1338(a).

6. This Court has personal jurisdiction over Talladium because Talladium regularly does and solicits business in New York and in this judicial district. Talladium has sold and/or offered to sell products that infringe the patents-in-suit, as alleged below, in New York and in this judicial district. Talladium also manages and controls an interactive website that enables customers, including those residing in New York and in this judicial district, to purchase infringing products online.

7. Venue in this district is proper under 28 U.S.C. Sections 1400 and 1391 because Talladium resides in this district and is subject to personal jurisdiction in this district. Talladium has committed acts of infringement in this district.

First Claim for Patent Infringement
(Infringement of the '759 Patent)

8. Ivoclar repeats and realleges the allegations set forth in paragraphs 1 through 7.

9. U.S. Patent No. 7,604,759, entitled “Process for Producing Dental Prostheses” (the “’759 Patent”), issued on October 20, 2009. Ivoclar is the owner by assignment of all right, title, and interest in the ’759 Patent. A copy of the ’759 Patent is attached as **Exhibit 1**.

10. Talladium has infringed and continues to infringe the ’759 Patent by making, using, selling, and/or offering for sale, in this district and elsewhere, discs for producing dental prostheses, including but not limited to, its Luminesse ZR product line, and by practicing a method used to create disks for producing dental prostheses.

11. Ivoclar informed Talladium that Talladium’s products and processes infringe the ’759 Patent. With knowledge of the ’759 Patent, and after receiving Ivoclar’s admonitions regarding infringement, Talladium continued to infringe the ’759 Patent.

12. Talladium’s actions in infringing the ’759 Patent have been, and continue to be, willful, deliberate, and/or in conscious disregard of the rights of Ivoclar, making this an exceptional case within the meaning of 35 U.S.C. Section 285.

13. As a result of Talladium’s infringing activities, Ivoclar has

sustained damages in an amount to be proven at trial.

14. Talladium will continue its infringing activities unless and until it is restrained and enjoined by this Court.

15. Talladium's infringing activities have caused, and will continue to cause, Ivoclar irreparable harm for which there is no adequate remedy at law.

**Second Claim for Patent Infringement
(Inducing Infringement of the '759 Patent)**

16. Ivoclar repeats and realleges the allegations set forth in paragraphs 1 through 16.

17. Talladium provides its infringing products to customers and other users with instructions and other information on how to use the infringing products in an infringing manner. Talladium's actions constitute inducement to infringe the '759 Patent whenever its customers or others use Talladium's products in an infringing manner.

18. Ivoclar informed Talladium that its products infringe the '759 Patent. With knowledge of the '759 Patent, and after receiving Ivoclar's admonitions regarding infringement, Talladium continued to infringe the '759 Patent, and continued to induce others to infringe the '759 Patent.

19. Talladium's actions in infringing the '759 Patent have been, and continue to be, willful, deliberate, and/or in conscious disregard of the rights of Ivoclar, making this an exceptional case within the meaning of 35 U.S.C. Section 285.

20. As a result of Talladium's infringing activities, Ivoclar has

sustained damages in an amount to be proven at trial.

21. Talladium will continue its infringing activities unless and until it is restrained and enjoined by this Court.

22. Talladium's infringing activities have caused, and will continue to cause, Ivoclar irreparable harm for which there is no adequate remedy at law.

Jury Demand

23. Ivoclar demands trial by jury on all matters triable by jury.

WHEREFORE, Ivoclar is entitled to judgment for the following relief:

(1) Declaring that Talladium has directly infringed one or more claims of the '759 Patent.

(2) Declaring that Talladium has induced others to infringe one or more claims of the '759 Patent.

(3) Granting an injunction, under 35 U.S.C. Section 283, preliminarily and permanently enjoining Talladium, its officers, directors, agents, servants, employees, attorneys, subsidiaries, affiliates, and all those acting in concert with or under or through them, from making, using, selling, and/or offering for sale any systems or products that infringe one or more claims of the '759 Patent, or otherwise directly or indirectly committing further acts of infringement of that Patent.

(4) Ordering an accounting for damages arising from Talladium's acts of infringement.

(5) Awarding damages, including treble damages, under 35 U.S.C. Sections 284 and 285, with interest.

(6) Finding that Talladium's infringement is willful, that this is an exceptional case, and awarding reasonable attorneys' fees to Ivoclar under 35 U.S.C. Section 285.

(7) Such further relief as this Court deems proper.

Dated: December 6, 2013

HODGSON RUSS LLP
Attorneys for Ivoclar Vivadent, Inc.

By: s/Robert J. Fluskey, Jr.
Robert J. Fluskey, Jr.
rfluskey@hodgsonruss.com
The Guaranty Building
140 Pearl Street, Suite 100
Buffalo, New York 14202
Telephone: (716) 856-4000